Trial Profile
Comparison of antibody responses to the Gardasil Quadrivalent Human Papillomavirus Vaccine in HIV-positive men in the Municipality of Campos dos Goytacazes, Rio de Janeiro, Brazil, 2016-2018
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2017
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- 21 Dec 2017 According to "Brazilian Clinical Trials Registry" planned date of last enrollment is 2018-07-15.
- 21 Dec 2017 New trial record